HK1118672A1 - Dietary fiber formulation and method of administration - Google Patents

Dietary fiber formulation and method of administration

Info

Publication number
HK1118672A1
HK1118672A1 HK08109894.0A HK08109894A HK1118672A1 HK 1118672 A1 HK1118672 A1 HK 1118672A1 HK 08109894 A HK08109894 A HK 08109894A HK 1118672 A1 HK1118672 A1 HK 1118672A1
Authority
HK
Hong Kong
Prior art keywords
dietary fiber
administration
fiber formulation
phgg
fos
Prior art date
Application number
HK08109894.0A
Other languages
English (en)
Inventor
John P Troup
Anne L Falk
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37835292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1118672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of HK1118672A1 publication Critical patent/HK1118672A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
HK08109894.0A 2005-10-24 2008-09-05 Dietary fiber formulation and method of administration HK1118672A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72976705P 2005-10-24 2005-10-24
US74212405P 2005-12-02 2005-12-02
PCT/US2006/041568 WO2007050656A2 (en) 2005-10-24 2006-10-23 Dietary fiber formulation and method of administration

Publications (1)

Publication Number Publication Date
HK1118672A1 true HK1118672A1 (en) 2009-02-20

Family

ID=37835292

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109894.0A HK1118672A1 (en) 2005-10-24 2008-09-05 Dietary fiber formulation and method of administration

Country Status (15)

Country Link
US (1) US8530447B2 (xx)
EP (1) EP1940243B1 (xx)
JP (2) JP5030960B2 (xx)
CN (1) CN103211230A (xx)
AT (1) ATE518430T1 (xx)
AU (1) AU2006306241B9 (xx)
BR (1) BRPI0617746A2 (xx)
CA (1) CA2626398C (xx)
DK (1) DK1940243T3 (xx)
HK (1) HK1118672A1 (xx)
IL (1) IL188846A0 (xx)
MY (1) MY144556A (xx)
PT (1) PT1940243E (xx)
RU (1) RU2395218C2 (xx)
WO (1) WO2007050656A2 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530447B2 (en) * 2005-10-24 2013-09-10 Nestec S.A. Dietary fiber formulation and method of administration
ES2650621T3 (es) 2008-10-17 2018-01-19 Sanofi-Aventis Deutschland Gmbh Combinación de una insulina y un agonista de GLP-1
MY159273A (en) * 2009-05-11 2016-12-30 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
TWI468171B (zh) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland 含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
WO2011142652A1 (en) * 2010-05-14 2011-11-17 Inqpharm Sdn Bhd Composition for reducing absorption of dietary fat
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012027214A1 (en) 2010-08-25 2012-03-01 Tate & Lyle Ingredients Americas Llc Synbiotic product
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
EP2478779A1 (en) 2011-01-24 2012-07-25 Biotechnobel Composition for providing beneficial health effects
EP2517699A1 (en) 2011-04-29 2012-10-31 Biotechnobel SA Composition for prevention and treatment of arthritis
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ITRM20110475A1 (it) * 2011-09-09 2013-03-10 Probiotical Spa Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104093413A (zh) * 2012-01-16 2014-10-08 葛兰素史克知识产权第二有限公司 治疗糖尿病和/或肥胖症的组合物和方法
KR101432884B1 (ko) * 2012-04-27 2014-08-21 재단법인 전남생물산업진흥원 돼지감자 지상부 추출물을 유효성분으로 함유하는 항염 조성물
CN102743420A (zh) * 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
UA116550C2 (uk) 2012-11-06 2018-04-10 Гонсалес-де Ла Торре Хав'єр Комбінація мікроінкапсульованого бактеріального консорціуму з протеолітичними ферментами для деградації глютену, її застосування та спосіб одержання вказаного бактеріального консорціуму
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
HUE042381T2 (hu) 2013-04-03 2019-06-28 Sanofi Sa Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
US10245294B2 (en) 2014-06-13 2019-04-02 Gratuk Technologies Pty Ltd Dietary supplement
CA2954662C (en) 2014-07-09 2024-03-19 Midori Usa, Inc. Oligosaccharide compositions and methods for producing thereof
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
RS64300B1 (sr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulacija fiksnog odnosa insulin glargina/liksisenatida
JP6427278B2 (ja) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ ｐｉｒｉｎポリペプチド及び免疫モジュレーション
CN108138122B (zh) 2014-12-23 2021-09-21 4D制药研究有限公司 免疫调控
MY188879A (en) 2015-01-26 2022-01-12 Kaleido Biosciences Inc Glycan therapeutics and related methods thereof
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP2016192913A (ja) * 2015-03-31 2016-11-17 株式会社東洋新薬 食物の胃からの排出遅延剤
WO2016172657A2 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SG10201912319SA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE045413T2 (hu) 2015-06-15 2019-12-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
DK3240554T3 (da) 2015-06-15 2019-10-28 4D Pharma Res Ltd Blautia stercosis og wexlerae til anvendelse til behandling af inflammatoriske og autoimmune sygdomme
NZ742787A (en) 2015-11-20 2020-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6551934B2 (ja) * 2015-12-18 2019-07-31 森永乳業株式会社 ビフィドバクテリウム属細菌および／または乳酸菌の増殖促進および／または減少抑制剤
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ES2731579T3 (es) 2016-03-04 2019-11-18 4D Pharma Plc Composiciones que comprenden cepas de blautia bacteriana para tratar hipersensibilidad visceral
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201617519D0 (en) * 2016-10-14 2016-11-30 Genetic Analysis As A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
FR3064483B1 (fr) * 2017-03-31 2022-06-03 Inra Administration perinatale de fructooligosaccharides a chaine courte afin d'empecher des troubles metaboliques lies a un regime alimentaire desequilibre a l'age adulte
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
CN107198250B (zh) * 2017-05-23 2019-03-12 北京瑞千景科技发展有限公司 改善肠道微生态预防慢性病组合物和均衡营养食品及应用
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
PT3638271T (pt) 2017-06-14 2021-01-05 4D Pharma Res Ltd Composições contendo estirpes bacterianas
HRP20220747T1 (hr) 2017-06-14 2022-10-14 4D Pharma Research Limited Pripravci koji sadrže bakterijske sojeve
MX2021008072A (es) * 2019-01-18 2021-08-16 Cp Kelco Us Inc Composicion prebiotica y su uso.
WO2021028743A1 (en) * 2019-08-14 2021-02-18 Jeyakodi Shankaranarayanan Nutritional compositions for management of irritable bowel disease/syndrome and improve gut health
CN110731432A (zh) * 2019-11-18 2020-01-31 青岛锦慧盛源生物科技发展有限公司 一种海藻益生元护胃饮料及其制备方法
JP2023503867A (ja) * 2019-11-27 2023-02-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ストレス障害を低減するための新規組成物
CN113615841A (zh) * 2021-07-27 2021-11-09 自然资源部第一海洋研究所 一种海带中可溶性膳食纤维在制备用于改善便秘的药物和功能性食品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6200950B1 (en) 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US6355609B1 (en) 1999-04-14 2002-03-12 Nestec S.A. Methods for stabilizing liquid nutritional products and products so stabilized
AU730929B2 (en) 1999-07-06 2001-03-22 Nestec S.A. Composition and method for prolonging the useful life of enteral feeding tubes
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1386546A1 (en) 2002-07-31 2004-02-04 Ca.Di.Group S.r.l. Association of prebiotics and colonic foods intended to help and keep the physiological health and the functional capacity of the intestine
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
GB0308104D0 (en) * 2003-04-08 2003-05-14 Novartis Nutrition Ag Organic compounds
GB0316550D0 (en) * 2003-07-15 2003-08-20 Forum Bioscience Holdings Ltd Sucrose substitute
WO2005035781A1 (en) * 2003-10-02 2005-04-21 Novartis Ag Prebiotic effect analysis
NO320546B1 (no) * 2003-12-12 2005-12-19 Nova Biotics As Prebiotiske kombinasjonsprodukter
JP2005247775A (ja) * 2004-03-05 2005-09-15 Sankyo Seiyaku Kogyo Kk 予防・治療用栄養組成物
CN1561757A (zh) * 2004-04-06 2005-01-12 李清山 复合膳食纤维粉
US8530447B2 (en) * 2005-10-24 2013-09-10 Nestec S.A. Dietary fiber formulation and method of administration

Also Published As

Publication number Publication date
EP1940243B1 (en) 2011-08-03
PT1940243E (pt) 2011-10-17
AU2006306241A1 (en) 2007-05-03
JP2009511506A (ja) 2009-03-19
CA2626398A1 (en) 2007-05-03
JP2012111771A (ja) 2012-06-14
BRPI0617746A2 (pt) 2011-08-02
WO2007050656A3 (en) 2007-07-12
RU2395218C2 (ru) 2010-07-27
IL188846A0 (en) 2008-04-13
EP1940243A2 (en) 2008-07-09
US8530447B2 (en) 2013-09-10
DK1940243T3 (da) 2011-11-14
CA2626398C (en) 2011-04-19
AU2006306241B2 (en) 2012-02-16
US20100168056A1 (en) 2010-07-01
AU2006306241B9 (en) 2012-03-08
ATE518430T1 (de) 2011-08-15
JP5030960B2 (ja) 2012-09-19
WO2007050656A2 (en) 2007-05-03
RU2008116057A (ru) 2009-10-27
MY144556A (en) 2011-09-30
CN103211230A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
HK1118672A1 (en) Dietary fiber formulation and method of administration
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
GB2451769B (en) Devices, systems, and methods for medicament delivery
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
EP2079500A4 (en) DEVICES AND METHODS FOR INFUSION
WO2007079448A3 (en) Three component carbohydrate vaccine
TW200614594A (en) Multi-portion socket and related apparatuses
UA93903C2 (ru) Производные тетрагидроизохинолина для повышения функции памяти
EP1998751A4 (en) Devices, systems and methods for medicament delivery
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
EP1948267A4 (en) FLUID DISPENSERS, SYSTEMS AND METHOD
GB0910105D0 (en) Devices, systems and methods for medicament delivery
EP1940491A4 (en) APPARATUSES, SYSTEMS AND METHODS FOR DELIVERY OF FLUIDS
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
GB2451003B (en) Technique for using memory attributes
NO20082097L (no) Farmasoytiske sammensetninger
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
RS50832B (sr) Agens oleogela sa sadržajem triterpena, oleogel sa sadržajem triterpena i postupak za proizvodnju oleogela sa sadržajem triterpena
GB201108993D0 (en) Devices, systems and methods for medicament delivery
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
UA99719C2 (ru) Вакцина для собак против болезни лайма
IL195907A0 (en) Protein-binding methotrexate derivatives, and medicaments containing the same
GB2456245B (en) Devices,systems and methods for medicament delivery

Legal Events

Date Code Title Description
REV Revocation after opposition